# Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

> **NCT06249191** · PHASE1,PHASE2 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- High Grade B-Cell Lymphoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **PROCEDURE:** Echocardiography
- **DRUG:** Etoposide
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Mosunetuzumab
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Prednisone
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT06249191
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-13
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06249191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06249191, "Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06249191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*